199 related articles for article (PubMed ID: 34599865)
1. Effects of sevelamer carbonate versus calcium acetate on vascular calcification, inflammation, and endothelial dysfunction in chronic kidney disease.
Mason DL; Godugu K; Nnani D; Mousa SA
Clin Transl Sci; 2022 Feb; 15(2):353-360. PubMed ID: 34599865
[TBL] [Abstract][Full Text] [Related]
2. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.
Rastogi A
Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):322-42. PubMed ID: 24327730
[TBL] [Abstract][Full Text] [Related]
3. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
4. Effects of phosphate binders in moderate CKD.
Block GA; Wheeler DC; Persky MS; Kestenbaum B; Ketteler M; Spiegel DM; Allison MA; Asplin J; Smits G; Hoofnagle AN; Kooienga L; Thadhani R; Mannstadt M; Wolf M; Chertow GM
J Am Soc Nephrol; 2012 Aug; 23(8):1407-15. PubMed ID: 22822075
[TBL] [Abstract][Full Text] [Related]
5. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
6. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients.
Caglar K; Yilmaz MI; Saglam M; Cakir E; Acikel C; Eyileten T; Yenicesu M; Oguz Y; Vural A; Carrero JJ; Axelsson J; Lindholm B; Stenvinkel P
Clin J Am Soc Nephrol; 2008 Jan; 3(1):61-8. PubMed ID: 18057307
[TBL] [Abstract][Full Text] [Related]
7. Effects of phosphorus-restricted diet and phosphate-binding therapy on outcomes in patients with chronic kidney disease.
Russo D; Bellasi A; Pota A; Russo L; Di Iorio B
J Nephrol; 2015 Feb; 28(1):73-80. PubMed ID: 24599830
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Prajapati VA; Galani VJ; Shah PR
Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
[TBL] [Abstract][Full Text] [Related]
10. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial.
Yilmaz MI; Sonmez A; Saglam M; Yaman H; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Yenicesu M; Mallamaci F; Zoccali C
Am J Kidney Dis; 2012 Feb; 59(2):177-85. PubMed ID: 22137672
[TBL] [Abstract][Full Text] [Related]
11. Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia.
De Schutter TM; Behets GJ; Geryl H; Peter ME; Steppan S; Gundlach K; Passlick-Deetjen J; D'Haese PC; Neven E
Kidney Int; 2013 Jun; 83(6):1109-17. PubMed ID: 23486515
[TBL] [Abstract][Full Text] [Related]
12. Effect of cross-linked chitosan iron (III) on vascular calcification in uremic rats.
de Castro BBA; do Carmo WB; de Albuquerque Suassuna PG; Carminatti M; Brito JB; Dominguez WV; de Oliveira IB; Jorgetti V; Custodio MR; Sanders-Pinheiro H
Exp Biol Med (Maywood); 2018 May; 243(9):796-802. PubMed ID: 29763365
[TBL] [Abstract][Full Text] [Related]
13. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease.
Fathallah-Shaykh S; Drozdz D; Flynn J; Jenkins R; Wesseling-Perry K; Swartz SJ; Wong C; Accomando B; Cox GF; Warady BA
Pediatr Nephrol; 2018 Feb; 33(2):325-333. PubMed ID: 28900759
[TBL] [Abstract][Full Text] [Related]
15. [Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of phosphate binders on vascular calcification].
Hanafusa N
Clin Calcium; 2015 May; 25(5):711-21. PubMed ID: 25926575
[TBL] [Abstract][Full Text] [Related]
16. Short-term efficacy of sevelamer versus calcium acetate in patients with chronic kidney disease stage 3-4.
Gulati A; Sridhar V; Bose T; Hari P; Bagga A
Int Urol Nephrol; 2010 Dec; 42(4):1055-62. PubMed ID: 20020207
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
Evenepoel P; Selgas R; Caputo F; Foggensteiner L; Heaf JG; Ortiz A; Kelly A; Chasan-Taber S; Duggal A; Fan S
Nephrol Dial Transplant; 2009 Jan; 24(1):278-85. PubMed ID: 18820280
[TBL] [Abstract][Full Text] [Related]
18. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis.
Goldsmith DR; Scott LJ; Cvetković RS; Plosker GL
Drugs; 2008; 68(1):85-104. PubMed ID: 18081374
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis.
Spoendlin J; Paik JM; Tsacogianis T; Kim SC; Schneeweiss S; Desai RJ
JAMA Intern Med; 2019 Jun; 179(6):741-749. PubMed ID: 31058913
[TBL] [Abstract][Full Text] [Related]
20. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
